Results 111 to 120 of about 39,319 (333)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood, 2020
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
S. Treon, J. Castillo, A. Skarbnik, J. Soumerai, I. Ghobrial, M. L. Guerrera, K. Meid, Guang Yang   +7 more
semanticscholar   +1 more source

Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves [PDF]

, 2016
To the Editor: Makkar et al. (Nov. 19 issue)(1) report possible subclinical leaflet thrombosis in up to 40% of patients involved in a clinical trial of transcatheter aortic-valve replacement (TAVR).
Burriesci, Gaetano, Colli, Andrea, Ducci, Andrea   +2 more
core   +2 more sources

Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells. [PDF]

, 2019
Selective differentiation of naive T cells into multipotent T cells is of great interest clinically for the generation of cell-based cancer immunotherapies. Cellular differentiation depends crucially on division state and time.
Bendall, Sean C, Borges, Luciene, Good, Zinaida, Nolan, Garry P, Sahaf, Bita, Samusik, Nikolay, Tibshirani, Robert, Vivanco Gonzalez, Nora   +7 more
core  

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Blood Cancer Journal, 2021
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain.
Natalia Timofeeva, Varsha Gandhi
doaj   +1 more source

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias

Frontiers in Pharmacology
The Bruton’s Tyrosine Kinase Inhibitor, ibrutinib, has been widely employed due to its significant efficacy in B-cell lymphoma. However, the subsequent cardiac complications, notably atrial fibrillation (AF) and ventricular arrhythmias (VAs),associated ...
Yilin Pan, Yilin Pan, Yanan Zhao, Hangyu Ren, Hangyu Ren, Xintong Wang, Caixia Liu, Beibei Du, Kumaraswamy Nanthakumar, Ping Yang   +9 more
doaj   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources